Portage, Michigan, July 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for its second quarter of fiscal year 2025 on Thursday, July 31, 2025.  A press release will be issued at approximately 4:05 p.m. ET and available at Stryker - Press Releases that day. The press release will include summary financial information for the company’s second quarter that ended June 30, 2025. Stryker will host a webcast at 4:30 p.m. ET on Thursday, July 31, 2025, to discuss its ...

Key Takeaways SYK gains FDA clearance for InCompass, a total ankle system for advanced ankle arthritis. SYK's InCompass combines tech from Inbone and Infinity for better alignment and surgical flow. SYK's Foot & Ankle unit anchors orthopaedics growth with $2.4 billion in Q1 sales.Stryker (SYK) recently received FDA clearance for its InCompass Total Ankle System, marking a pivotal expansion in the company's Foot & Ankle portfolio. Designed to address end-stage ankle arthritis, the InCompass system combines ...

证券研究报告：医药生物 | 公司深度报告 发布时间：2025-06-27 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 38.50 | | --- | --- | | 总股本/流通股本（亿股）1.20 | / 1.20 | | 总市值/流通市值（亿元）46 | / 46 | | 52 周内最高/最低价 | 43.47 / 25.73 | | 资产负债率(%) | 10.6% | | 市盈率 | 34.38 | | 第一大股东 | 青岛普奥达企业管理服 | | 务有限公司 | | 研究所 分析师:盛丽华 SAC 登记编号:S1340525060001 Email:shenglihua@cnpsec.com 研究助理:陈峻 SAC 登记编号:S1340123110013 Email:chenjun@cnpsec.com 海泰新光(688677) 海外库存消化拐点已至，未雨绸缪化解关税风险 l 公司致力于探索光学技术与医学、工业及激光、生物识 别等多领域的融合创新 海泰新光主要从事医用内窥镜器械和光学产品的研发、生产和销 售。公司致力于探索光学技术与医学、工业及激光、生物识别 ...

Steady growth and dividend increases over decades can make investors remarkably wealthy. Volatility is a part of life for long-term investors. The reasons the market goes up or down change, but the constant is that high-quality stocks, businesses that increasingly make more money over time, will reward investors if you wait long enough. The market's occasional ups and downs are a feature, not a bug. Use market downturns as opportunities to invest in long-term winners that continue to grow, pay, and raise di ...

2025年5月20日，美国国际贸易委员会(ITC)投票决定对特定球囊扩张装置、系统及其组件启动337调查 (调查编码：337-TA-1449)。美国Entellus Medical,Inc.、美国Stryker Corporation及其销售公司向美国ITC 提出337立案调查申请，主张对美出口、在美进口和在美销售的该产品违反了美国337条款，请求美国 ITC发布有限排除令、禁止令。德国Fiagon GmbH、德国Fiagon AG Medical Technologies、美国Fiagon NA Corporation和美国Fiagon NA,LLC为列名被告。美国国际贸易委员会将于立案后45天内确定调查结 束期。除美国贸易代表基于政策原因否决的情况外，美国国际贸易委员会在337案件中发布的救济令自 发布之日生效并于发布之日后的第60日起具有终局效力。(中国贸易救济信息网) ...

Stryker (SYK) recently received FDA clearance for its OptaBlate BVN Basivertebral Nerve Ablation System (OptaBlate BVN), a significant milestone in the treatment of chronic vertebrogenic lower back pain. The addition of the OptaBlate BVN to Stryker's pain portfolio expands its advanced pain therapy solutions for patients and represents the intersection of two of the company’s core competencies: radiofrequency ablation technology and vertebral access.As back pain remains one of the most prevalent and debilit ...

Stryker's first basivertebral nerve ablation system targets the basivertebral nerve to provide relief from chronic* vertebrogenic low back pain.PORTAGE, Mich., May 19, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain re ...

Stryker Corporation (NYSE:SYK) Bank of America Securities 2025 Global Healthcare Conference May 13, 2025 4:40 PM ET Company Participants Preston Wells - Chief Financial Officer Jason Beach - Vice President, Finance and Investor Relations Conference Call Participants Travis Steed - Bank of America Travis Steed [abrupt start] the Bank of America medical device analyst and continuing our day of Medtech conversations. Next up we've got Stryker Corporation, Preston Wells, newly appointed CFO; and Jason Beach, VP ...

Stryker (SYK) 2025 Conference May 13, 2025 04:40 PM ET Speaker0 Travis Steed, the Bank of America Medical Device Analyst and continuing our day of med tech conversations. Next up, we've got Stryker Corporation, Preston Wells, newly appointed CFO, and Jason Beach, VP of Finance and IR. Welcome. Thanks for joining Yeah, Speaker1 thanks for having us. Speaker0 So Preston, maybe I'll start out in a new CFO. You've been a Stryker a while. Investors have known you for a while in your former roles, and it seems li ...

Core Viewpoint - The investment thesis for Stryker Corporation (NYSE: SYK) is based on the anticipated launch of Mako shoulder and spine applications, which has contributed to a significant stock price increase of over 28% since December 2023, outperforming the S&P 500 index [1] Company Summary - Stryker Corporation's stock has seen a notable increase of more than 28% since the presentation of the Buy thesis in December 2023 [1] - The company's performance is linked to the potential launch of new applications for its Mako robotic surgical system, specifically in shoulder and spine procedures [1] Market Performance - Stryker's stock performance has outpaced the S&P 500 index, indicating strong market confidence in the company's future growth prospects [1]